Integrative Bioinformatics Study Reveals Tangeretin Targets and Molecular Mechanisms Against Metastatic Breast Cancer

Adam Hermawan (adam/apt@ugm.ac.id)  
Universitas Gadjah Mada Fakultas Farmasi  
https://orcid.org/0000-0001-5851-3691

Herwandhani Putri  
Universitas Gadjah Mada Fakultas Farmasi

Naufa Hanif  
Universitas Gadjah Mada Fakultas Farmasi

Muthi Ikawati  
Universitas Gadjah Mada Fakultas Farmasi

Research

Keywords: tangeretin, metastatic breast cancer, bioinformatics, potential targets, drug development

DOI: https://doi.org/10.21203/rs.3.rs-55381/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Agents that target metastasis are important to improve treatment efficacy in patients with breast cancer. Tangeretin, a citrus flavonoid, exhibits antimetastatic effects on breast cancer cells, but its molecular mechanism remains unclear.

**Results:** Tangeretin targets were retrieved from PubChem, whereas metastatic breast cancer regulatory genes were downloaded from PubMed. In total, 58 genes were identified as potential therapeutic target genes of tangeretin (PTs). Gene ontology analysis with Webgestalt showed that the PTs participate in the biological process of stimulus response, are the cellular components of the nucleus and the membrane, and play molecular roles in enzyme regulation. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis revealed that the PTs regulate the PI3K/Akt pathway. Genetic alterations for each target gene were MTOR (3%), NOTCH1 (4%), TP53 (42%), MMP9 (4%), NFKB1 (3%), PIK3CA (32%), PTGS2 (15%), and RELA (5%). The Kaplan–Meier plot displayed that patients with low mRNA expression levels of MTOR, TP53, MMP9, NFKB1, PTGS2, and RELA and high expression of PIK3CA had a significantly better prognosis than their counterparts. Further validation of gene expression by using GEPIA revealed that the mRNA expression of MMP9 was significantly lower in breast cancer tissues than in normal tissues, whereas the mRNA expression of PTGS2 showed the opposite. Analysis with ONCOMINE demonstrated that the mRNA expression levels of MMP9 and NFKB1 were significantly higher in metastatic breast cancer cells than in normal tissues. The results of molecular docking analyses revealed the advantage of tangeretin as an inhibitor of PIK3CA, MMP9, PTGS2, and IKK.

**Conclusion:** Tangeretin inhibits metastasis in breast cancer cells by targeting TP53, PTGS2, MMP9, and PIK3CA and regulating the PI3K/Akt signaling pathway. Further investigation is needed to validate the results of this study.

**Background**

Breast cancer is a common cause of death among women worldwide (1). Breast cancer was initially considered a local disease, but it can metastasize to lymph nodes and other organs in the body, which is fatal to patients (2). Understanding the molecular mechanisms underlying metastasis is important to improve the clinical management of breast cancer (3). Accordingly, molecular therapeutic agents that target metastasis must be developed to enhance the effectiveness of breast cancer therapy (4).

Tangeretin, a citrus flavonoid (Fig. 1A), may be developed as a specific molecular-targeted anticancer agent because of its antimetastatic effects (5) on cancer cells (6–8). In specific, this compound inhibits metastases of skin, breast, and gastric cancer cells. Tangeretin hampers the invasion of MO4 mouse cells to the embryonic chick heart (9). It also inhibits lung metastasis in melanoma B16F10 cell xenograft (10) and metastasis in 7,12-dimethylbenz(a)anthracene-induced rat breast cancer (11). Moreover, tangeretin alleviates epithelial–mesenchymal transition (EMT), invasion, and migration in gastric cancer cells by downregulating Notch-1, Jagged1/2, Hey-1, and Hes-1 (12). Nonetheless, the molecular target of tangeretin for the metastatic inhibition of breast cancer remains unknown.

In this study, we used a bioinformatics approach to obtain the tangeretin protein target data from PubChem, the metastatic breast cancer regulatory genes from PubMed, and the potential target genes of tangeretin against metastatic breast cancer (PT). We performed gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, and protein–protein interaction (PPI) network analyses and selected hub genes on the basis of the highest degree score. Selected PTs were further analyzed for their prognostic values by using Kaplan–Meier survival plot and GEPIA. Corroboration of the accuracy of the selected PT in metastatic breast cancer samples was performed using ONCOMINE. Alterations in the selected genes were analyzed using the public database cBioPortal. Molecular docking studies were conducted to identify the interaction between tangeretin and PT. The results of this study emphasized the potential of tangeretin as an antimetastatic agent in breast cancer therapy.

**Results**

**GO and KEGG pathway enrichment analyses**

GO analysis was conducted with Webgestalt on the basis of three criteria, namely, biological process, cellular component, and molecular function (Fig. 1C). The PTs participate in the biological processes of stimulus response, metabolic process, and cell proliferation. In addition, the PTs are cellular components of the nucleus and the membrane. The PTs also play a molecular role in protein binding, ion binding, and enzyme regulator activity. Pathway enrichment by KEGG of the PTs (Supplementary Table 3) showed the regulation of ~106 pathways, including PI3K-Akt, breast cancer, and TNF signaling pathway (Supplementary Table 4). Several PTs were involved in PI3K-Akt signaling (e.g., PIK3CA, PRKAA2, RELA, and TP53), breast cancer pathway (e.g., AKT1, MTOR, NOTCH1, PIK3CA, and TP53), and TNF signaling pathway (e.g., MMP9, NFKB1, PIK3CA, PTGS2, and RELA) (Supplementary Table 5).

**Analysis of PPI network and selection of hub genes**
A PPI network was constructed from 58 proteins (confidence level of 0.4) consisting of 58 nodes, 409 edges, PPI enrichment value of <1.10e-16, and average local clustering coefficient of 0.62 (Fig. 2A). The top 20 highest degree score genes, also known as hub genes, were identified, including TP53, AKT1, STAT3, IL6, and MAPK1 (Fig. 2B, Table 1).

### Table 1
Top 20 hub genes ranked by Degree method, analyzed by CytoHubba

| Rank | Gene symbol | Gene name                                | Score |
|------|-------------|------------------------------------------|-------|
| 1    | TP53        | Cellular tumor antigen p53                | 40    |
| 2    | AKT1        | RAC-alpha serine/threonine-protein kinase | 37    |
| 3    | IL6         | Interleukin-6                             | 33    |
| 4    | STAT3       | Signal transducer and activator of transcrip | 31    |
| 4    | MAPK1       | Mitogen-activated protein kinase 1        | 31    |
| 6    | MAPK8       | Mitogen-activated protein kinase 8        | 29    |
| 7    | JUN         | Transcription factor AP-1                | 27    |
| 8    | CCND1       | G1/S-specific cyclin-D1                  | 26    |
| 8    | CASP3       | Caspase-3                                | 26    |
| 8    | MAPK3       | Mitogen-activated protein kinase 3        | 26    |
| 11   | VEGFA       | Vascular endothelial growth factor A      | 24    |
| 12   | INS         | Insulin                                  | 23    |
| 13   | MTOR        | Serine/threonine-protein kinase mTOR      | 22    |
| 14   | MMP9        | Matrix metalloproteinase-9               | 21    |
| 15   | RELA        | Transcription factor p65                 | 20    |
| 16   | BCL2L1      | Bcl-2-like protein 1                     | 19    |
| 16   | CCL2        | C-C motif chemokine 2                    | 19    |
| 16   | MAPK14      | Mitogen-activated protein kinase 14       | 19    |
| 16   | PTGS2       | Prostaglandin G/H synthase 2              | 19    |
| 16   | HMOX1       | Heme oxygenase 1                         | 19    |

### Analysis of genetic alterations of potential target genes

Eight PTs were analyzed using cBioportal to explore their genomic alterations across breast cancer studies. MTOR, NOTCH1, PIK3CA, TP53, MMP9, NFKB1, PTGS2, and RELA were selected from KEGG pathway enrichment (Supplementary Table 5), whereas TP53, MTOR, MMP9, RELA, and PTGS2 were selected basing from the highest degree score using CytoHubba. The study BRCA INSERM 2016 (13) was selected for further analysis (Fig 3A). Genetic alterations for each target gene ranged from 3% to 42% of samples, including MTOR (3%), NOTCH1 (4%), TP53 (42%), MMP9 (4%), NFKB1 (3%), PIK3CA (32%), PTGS2 (15%), and RELA (5%) (Fig. 3B). Moreover, most gene alterations belonged to amplification, missense mutation, and truncating mutation (Fig. 3B). Further analysis of mutual exclusivity showed that only one gene pair (NOTCH1-RELA) exhibited significant co-occurrence ($p < 0.05$) in the breast cancer study by the INSERM 2016 project (Table 2), which indicated the pivotal role of NOTCH1 and RELA under tangeretin treatment.

### Table 2
Mutual exclusivity analysis of selected genes

| A    | B    | Log2 Odds Ratio | p-Value | Tendency |
|------|------|-----------------|---------|----------|
| NOTCH1 | RELA | >3              | <0.001  | Co-occurrence |

### Kaplan–Meier survival analysis

The Kaplan–Meier plot displayed that patients with low mRNA expression levels of MTOR ($p = 3.95x10^{-5}$), TP53 ($p = 0.00054$), MMP9 ($p = 0.0065$), NFKB1 ($p = 3.3x10^{-15}$), PTGS2 ($p = 0.0019$), and RELA ($p = 0.00088$) had significantly better overall survival rates than the opposite
group (Fig. 4). In addition, patients with a low mRNA level of NOTCH1 had better overall survival rates than those with a high mRNA level of NOTCH1, but the difference was not significant ($p = 0.91$). Moreover, patients with a low mRNA expression of PIK3CA showed significantly worse overall survival than the opposite group ($p = 2 \times 10^{-7}$).

**Validation of PTs in breast cancer and metastatic breast cancer samples**

Validation of PTs using GEPIA demonstrated that the mRNA expression of MMP9 was significantly higher in breast cancer tissues than in normal tissues (Fig. 5). In addition, the mRNA expression of PTGS2 was significantly lower in breast cancer tissues than in normal tissues. Furthermore, no significant difference in the mRNA expression levels of MTOR, NOTCH1, TP53, NFkB1, PIK3CA, and RELA was observed between breast cancer and normal tissue samples. The validation of target genes by using ONCOMINE showed that in samples from a TCGA study, the mRNA level of MMP9 was significantly higher in metastatic breast cancer cells than in normal breast cells with $p = 2.97 \times 10^{-16}$ (Fig. 6). In addition, samples from a study by Finak et al. (2008) showed that the mRNA level of NFkB1 was significantly higher in metastatic breast cancer cells than in normal breast cells ($p = 3.66 \times 10^{-14}$) (14). Moreover, the mRNA levels of MTOR, NOTCH1, TP53, PIK3CA, PTGS2, and RELA were not different between metastatic breast cancer cells and normal breast cells.

**Molecular docking**

Simulation of molecular docking and visualization of ligand-protein binding were conducted with M0E software. The protein targets, including PIK3Ca, MMP9, PTGS2, COX-2, and IKK, were selected on the basis of the KEGG pathway enrichment analysis, hub gene selection, survival analysis, PT validation, and the uniqueness as drug targets through literature research. Native ligands of each protein consist of PIK3C$\alpha$, MMP9, PTGS2, COX-2, and IKK complexes comprising ML9 (2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one), 7MR ((2R)-2-Amino-3,3,3-tri fluor-o-n-hydroxy-2-[(4-phenoxyphenyl sulfonyl) methyl] propanamide), COH (Protoporphyrin IX containing Co), HEM (Protoporphyrin IX containing Fe), and KSA (K-252A). PIK3Ca and MMP9 showed a slightly lower docking score than native ligands (ML9 and 7MR) (Table 3). The lower the docking score, the more potent the binding affinity of the ligand, implying that PIK3Ca and MMP9 tend to bend and react with tangeretin. Furthermore, tangeretin formed Arene-H between Ile932 and the compound with a bonding distance of 4.07, which was shorter than the Arene-H distance of ML9 with Ile932 (4.22) (Fig. 7). The higher docking score of tangeretin on PTGS2, COX-2, and IKK indicated lower binding affinity compared with native ligands (3X). This phenomenon can be ascribed to the fact that only one amino acid, Gln203, interacted with tangeretin on PTGS2 by Arene-H bond (Table 3). Otherwise, the native ligand of PTGS2 (COH) had four amino acids, which interacted through Arene-H (Gln203, Leu391), arene-cation (His207), and mental contact (His214) (Table 3). A similar phenomenon occurred to 6COX and IKK; the amino acid that interacted with tangeretin was fewer than the native ligands (Table 3).
Table 3
Molecular docking results of tangeretin against the protein targets of PIK3Cα, MMP9, PTGS2, COX-2, and IKK

| Protein   | Ligand Native | Tangeretin | Docking Score | RMSD (Å) | Ligand atom | Amino Acid | Binding Type | Distance | Docking Score | Ligand atom | Amino Acid | Binding Type | Distance |
|-----------|---------------|------------|---------------|-----------|-------------|------------|--------------|----------|---------------|-------------|------------|--------------|----------|
| PIK3Cα (4TV3) |               |            | -12.3229      | 1.9820    | C           | Ile848     | Arene-H      | 4.81     | -13.0943      | C           | Ile932     | Arene-H      | 4.07     |
|           |               |            |               |           | C           | Ile932     | Arene-H      | 4.22     |               | C           | Trp780     | Arene-H      | 7.51     |
|           |               |            |               |           | N           | Val851     | Backbone donor-acceptor | 4.10     |               | O           | Lys802     | Sidechain donor | 5.20     |
| MMP9 (2DW1) |               |            | -11.4732      | 1.7393    | C           | Leu188     | Arene-H      | 5.02     | -11.5442      | C           | Arg424     | Arene-H      | 6.41     |
|           |               |            |               |           | C           | Tyr423     | Arene-H      | 4.66     |               | O           | Tyr423     | Backbone donor | 5.82     |
|           |               |            |               |           | C           | Leu418     | Arene-H      | 4.10     |               | C           | Leu418     | Arene-H      | 4.42     |
|           |               |            |               |           | C           | 7MR502     | Arene-Arene | 4.37     |               | O           | Gln402     | Sidechain donor | 4.16     |
| PTGS2 (5F1A) |               |            | -14.8424      | 1.2559    | C           | Gln203     | Arene-H      | 3.61     | -11.8904      | C           | Gln203     | Arene-H      | 4.39     |
|           |               |            |               |           | C           | Leu391     | Arene-H      | 6.85     |               | O           | His207     | Arene-cation Mental contact | 5.61     |
|           |               |            |               |           | O           | His214     | Arene-cation Mental contact | 4.37     |               | O           | His214     | Arene-cation Mental contact | 5.61     |
| COX-2 (6COX) |               |            | -15.6490      | 1.0546    | O           | Asn382     | Sidechain donor | 5.26     | -12.0495      | C           | His386     | Arene-H      | 5.12     |
|           |               |            |               |           | O           | Thr212     | Backbone donor | 3.52     |               | O           | Gln203     | Arene-H      | 4.73     |
|           |               |            |               |           | O           | Gln454     | Sidechain donor | 5.73     |               | C           | Leu391     | Arene-H      | 6.40     |
|           |               |            |               |           | O           | His214     | Sidechain donor | 5.00     |               | C           | Asp103     | Backbone donor | 4.00     |
| IKK (4KIK)  |               |            | -14.0211      | 0.8232    | C           | Ile165     | Arene-H      | 3.89     | -10.4698      | C           | Ile165     | Arene-H      | 4.67     |
|           |               |            |               |           | C           | Leu21      | Arene-H      | 3.72     |               | O           | Leu21      | Arene-H      | 6.94     |
|           |               |            |               |           | O           | Cys99      | Backbone donor | 3.66     |               | O           | Cys99      | Backbone donor | 4.00     |
|           |               |            |               |           | C           | Val152     | Arene-H      | 6.07     |               | O           | Val152     | Backbone donor | 6.05     |
|           |               |            |               |           | C           | Val29      | Arene-H      | 5.80     |               | C           | Asp103     | Backbone acceptor | 4.40     |
|           |               |            |               |           | N           | Glu97      | Backbone acceptor | 6.18     |               |             |            |              |          |

Discussion

Metastasis is the main cause of death in patients with breast cancer. Utilizing a bioinformatics approach, we identified the PTs and mechanisms of tangeretin in inhibiting metastatic breast cancer. KEGG pathway enrichment analysis resulted in the PI3K-Akt pathway regulated by PT. The top 20 genes with the highest degree score were TP53, AKT1, STAT3, IL6, and MAPK1. Eight PTs that were selected from the KEGG pathway enrichment and with the highest degree scores were analyzed using cBioportal to explore their genomic alterations across breast cancer studies. The highest genetic alterations were found in TP53 (42%), PIK3CA (32%), and PTGS2 (15%). These results indicated the pivotal role of these three genes in the antimetastatic effects of tangeretin on breast cancer cells.

The Kaplan–Meier plot indicated that patients with low mRNA expression levels of MTOR (p = 3.95 x 10^-5), TP53 (p = 0.00054), MMP9 (p = 0.0065), NFKB1 (p = 3.3 x 10^{-16}), PTGS2 (p = 0.0019), and RELA (p = 0.00088) had better prognosis than the opposite group, whereas patients with low mRNA expression of PIK3CA (p = 2 x 10^{-7}) had a worse prognosis than the opposite group. Validation of gene expression with GEPIA indicated that the mRNA expression of MMP9 was significantly higher in breast cancer tissues than in normal breast tissues, whereas the mRNA
expression of PTGS2 was significantly lower in breast cancer tissues than in normal breast tissues. Validation of PT with ONCOMINE indicated that in samples from a TCGA study, the mRNA level of MMP9 was significantly upregulated in metastatic breast cancer tissues than in normal breast tissues \((p = 2.97 \times 10^{-19})\). Moreover, samples from a study by Finak et al. (2008) showed that the mRNA level of NFKB1 was significantly higher in metastatic breast cancer cells than in normal breast cells \((p = 3.66 \times 10^{-14})\) (14). Collectively, these results indicate the important roles of TP53, PTGS2, MMP9, and NFKB1 in the antimetastatic effects of tangeretin on metastatic breast cancer cells.

This study emphasized the important role of the PI3K/Akt pathway and related genes (TP53, PTGS2, NFKB1, and PIK3CA) in the antimetastatic effects of tangeretin on metastatic breast cancer cells. Here we discussed the important roles of those genes and their potential as tangeretin targets against metastatic breast cancer cells. TP53 encodes tumor protein p53, a tumor suppressor gene (15). Mutation in TP53 occurs in human epidermal growth factor receptor 2-positive (15), estrogen receptor-positive, and progesterone-positive breast cancer subtypes (16). In addition, the TP53 gene is mutated in 80% of patients with triple-negative breast cancer (17). Loss of p53 or gain of mutant p53 promotes tumor progression and metastasis (18). In addition, loss of p53 induces metastasis via activation of Wnt signaling (19). Moreover, the mutation in TP53 can promote immunogenic activity in breast cancer (20).

Tangeretin regulates p53 expression. Tangeretin increases p53 expression in AGS human gastric cancer cells (21). In addition, tangeretin treatment induces the upregulation of p53 and inhibits metastasis in 7,12-dimethylbenz(a)anthracene-induced rat breast tumor (11). However, the study of TP53 mutation, metastasis, and tangeretin treatment remains elusive.

MMP9 encodes matrix metalloproteinase9 (MMP9), a protease that cleaves the extracellular matrix and is involved in angiogenesis, invasion, and metastasis (22). MMP-9 is dominantly synthesized by tumor cells (23). MMP9 is upregulated in breast cancer cells compared with normal tissue and is correlated with metastasis and recurrence in breast cancer (24). Thus, inhibition of MMP activity is an effective way of preventing metastasis in patients with breast cancer (25). A previous study demonstrated that tangeretin inhibits metastasis in rat mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene by downregulating MMP2, MMP9, and VEGF (11). In addition, tangeretin inhibits the expression and activity of MMP9 in rats with pilocarpine-induced seizures (26). Future study of tangeretin effect against MMP9 activity in metastatic breast cancer is warranted.

PTGS2 encodes prostaglandin-endoperoxide synthase 2, also known as cyclooxygenase-2 (COX-2), which participates in prostaglandin synthesis, regulates inflammation, and promotes cancer progression, invasion, and migration (27, 28). COX-2 is expressed in 40% of human metastatic breast cancers (29). A previous study showed that tangeretin inhibits COX-2 expression induced by IL-1beta in A549 lung cancer cells by inhibiting NF-kB, p38 MAPK, JNK, and PI3K signaling (30). Moreover, tangeretin inhibits UVB-induced COX-2 expression by inhibiting MAPK activation and reactive oxygen species elevation (31). Recently, an in silico study has demonstrated that tangeretin can inhibit COX-2 (32). Nevertheless, the effects of tangeretin on COX-2 activity and expression in metastatic breast cancer cells need further exploration.

NFKB1 encodes the nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, a member subunit of NFKB (33). NFKB1 forms various dimeric complexes with other sub units to activate NFkB signaling that regulates several biological processes, including inflammation, senescence, apoptosis, cell survival, and cancer progression (33). NFKB1 plays a role in cancer progression and is a potential target for cancer therapy (34). NFkB signaling is important in the invasiveness of inflammatory breast cancer (35), as well as in chemoresistance mechanism and invasive breast cancer (36). Moreover, NFKB1/RELA induces breast cancer progression by upregulating ETS1 (37). A previous study showed that tangeretin treatment reduces the phosphorylation of IkB-a and IKK-β, as well as the nuclear translocation of the p65 subunit of NF-kB in lipopolysaccharide-stimulated microglial cells (38). Hence, the inhibitory effect of tangeretin on invasion and metastasis by targeting NFkB signaling needs to be explored in future studies.

PIK3CA encodes phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), also known as p110α, a member of the phosphoinositide 3-kinase (PI3K) family (39). The PI3K signaling pathway is involved in the biological processes of cellular proliferation, apoptosis, survival, motility, and metastasis (40, 41). Mutation in PIK3CA is present in most solid tumors (42) and is found in 12–15% of patients with breast cancers (43). A recent study has shown that mutation in PIK3CA corresponds to a poor prognosis in patients with hormone receptor-positive metastatic breast cancer but a good prognosis in patients with triple-negative breast cancer (44).

Tangeretin inhibits the PI3K signaling pathway. Tangeretin enhances the sensitivity of cisplatin in human ovarian cancer cells by downregulating the PI3K/Akt signaling pathway (45). Tangeretin also inhibits the proliferation and migration of aortic smooth muscle cells through suppressing the PI3K/AKT signaling pathway (46). Another study showed that tangeretin poses a potent neuroprotective activity by triggering the PI3K/Akt signaling pathway in pilocarpine-induced seizures rats (26). Tangeretin also inhibits PI3K and Notch signaling in neonatal asthmatic mice (47). Moreover, tangeretin inhibits EMT in PC-3 prostate cancer cells by downregulating the PI3K/Akt/mTOR pathway (48). However, the effects of tangeretin on PI3K signaling and of PIK3CA mutation on metastatic breast cancer cells need to be clarified in future studies.

KEGG pathway enrichment analysis indicated that the PTs regulate the PI3K/Akt signaling pathway. In this study, we discussed the cross-talk between the PTs in the regulation of the PI3K/Akt pathway. COX2 promotes cell survival by activating the PI3K/Akt pathway in human lung cancer cells (49). Inhibition of COX2 blocks PI3K/AKT kinase activity in ovarian cancer (50) and hepatocellular carcinoma cells (51). In addition,
PI3K/Akt kinase activity induces COX2 expression in lipopolysaccharide-induced murine adenocarcinoma cells (52). Furthermore, COX2 and PI3K are associated with the progression of colon cancer (53).

PI3K/Akt and mTOR signaling pathways are essential for maintaining the proliferation and survival of cancer cells (54). A recent study has shown that activation of PI3K/AKT/mTOR signaling increases hepatocellular carcinoma resistance to radiotherapy (55). On the one hand, activation of the PI3K/Akt pathway leads to the transcriptional activity of NFkB (56). On the other hand, NFkB activity is important for oncogenic transformation induced by PI3K/Akt signaling (56). Mutation in PI3K signaling regulator, including PIK3CA, leads to cytokine expression upon growth factor deprivation in an NFkB-dependent manner (57). Furthermore, PI3K/Akt/JNK/NFkB signaling plays a pivotal role in the expression of MMP-9 and enlargement in human limbal epithelial cells (58).

Activation of the PI3K/PTEN/AKT/mTOR pathway promotes invasion and metastasis by increasing the expression of MMP9 in hepatocellular carcinoma cells (59) and human breast cancer cells (60). Furthermore, inhibition of Notch1 signaling reduces the proliferation, migration, and invasion of human breast cancer cells by decreasing PI3K/Akt activity (Li et al., 2016). p53 participates in the regulation of cell survival by blocking the PI3K/AKT signaling pathway in cancer cells (61). Moreover, activating mutations in PIK3CA promotes the stimulation of p53 signaling (62). A previous study showed that PI3K/Akt promotes p53 translation in cancer development (63). Inhibition of PI3K/Akt signaling leads to p53 upregulation in leukemic cancer cells (64). A recent study has reported p53 upregulation due to PI3K/Akt signaling inhibition in EMT inhibition in liver cancer cells (65). Collectively, the PI3K/Akt signaling pathway is important for the regulation of metastatic breast cancer and is a potential target of tangeretin in inhibiting metastasis. However, whether or not the inhibitory effect of tangeretin on PI3K/Akt signaling is related to metastatic breast cancer demands further exploration.

In this study, molecular docking analysis emphasized the potential target of tangeretin in inhibiting metastatic breast cancer cells. Tangeretin was shown to inhibit PIK3CA, MMP9, COX2, and IKK. One of the unique targets for cancer drug discovery is PIK3Ca because of the high prevalence of its mutations in various human tumors and the progression in the development of personalized cancer medicines (66). The docking results on PIK3CA showed that the docking score of tangeretin was slightly lower than that of the native ligand ML9 ((2-amino-8-[trans-4-(2-hydroxyethoxy) cyclohexyl]-6- (6-methoxyPyridin-3-yl)- 4-methylpyrido[2,3-d]pyrimidin-7(8H)-one)). A low docking score represents a potent affinity of binding of the ligand, indicating that PIK3Ca tends to bend and react with tangeretin instead of the native ligand. The docking results of tangeretin on PIK3CA formed Arene-H between Ile932 and the compound with a bonding distance of 4.07, which was shorter than the Arene-H distance of ML9 with ile932 (4.22) (Table 3). Furthermore, tangeretin has donor side chains, whereas native ligands have donor–acceptor backbones. Hence, this donor side chain is useful in increasing tangeretin binding to PIK3CA. The docking results on MMP9 showed that docking score of tangeretin was lower than that of the native ligand 7MR ((2R)-2-Amino-3,3,3-triuoro-n-hydroxy-2-{[(4-phenoxyphenyl) sulfonyl] methyl} propanamide)). This result is due to the differences in bond types. In specific, the native ligand has a type of arene–arene bonding, whereas tangeretin has backbone and sidechain donors. This result is in line with the findings of Roshini et al. (2018) that tangeretin, when combined with zinc oxide (Tan-ZnO QDs), can downregulate the expression of metastasis markers, such as MMP2, MMP9, and VEGF (67). Tangeretin showed a higher docking score than native ligands on PTGS2, COX-2, and IKK, suggesting that tangeretin has a lower binding affinity than the native ligands COH (Protoporphyrin IX containing Co), HEM (Protoporphyrin IX containing Fe), and KSA (K-252A) (Table 3).

Molecular docking results on PTGS2 showed that only one amino acid, Gln203, interacted with tangeretin by Arene-H bond (Table 3). Otherwise, the native ligand of PTG52 (COH) had four amino acids, which interacted by Arene-H (Gln203, Leu391), arene-cation (His207), and mental contact (His214) (Table 3). The results of molecular docking on COX2 showed a lower docking score of tangeretin than native ligands because fewer amino acids on 6COX interacted with tangeretin than native ligands.

The IKK complex plays a vital role in NFkB signaling and is an important target for cancer therapy (68, 69). Molecular docking results on IKK with the PDB code of 4KIK showed that the docking scores of tangeretin were lower than those of native ligands because of the lack of one type of bonding, namely, backbone acceptor. However, tangeretin still inhibited COX2 and IKK activities. This results is supported by the previous finding of Chen et al. (2007) that tangeretin inhibits IL-1β-induced COX-2 protein expression by suppressing COX-2 gene expression(30). Another study also showed that tangeretin significantly inhibits the activation of IKK-β induced by LPS (38). Altogether, although the binding affinity of tangeretin is not much more robust than native ligands, it still has the potency to inhibit PTGS2, COX2, and IKK activities.

Conclusions

Tangeretin inhibits metastasis in breast cancer cells by targeting TP53, PTGS2, MMP9, and PIK3CA. Molecular docking studies revealed the potential of tangeretin as an inhibitor of MMP9 and PTGS2. Furthermore, PI3K/Akt signaling is a potential target of tangeretin in inhibiting breast cancer metastasis. Future in vitro and in vivo investigations are needed to validate the results of this study.

Methods

Data collection and processing
We downloaded 93 tangeretin targets from PubChem (Supplementary Table 1) and 2263 metastatic breast cancer regulatory genes from PubMed (Supplementary Table 2). A Venn diagram was generated using the tangeretin targets from PubChem and the metastatic breast cancer regulatory genes from PubMed, which resulted in 58 genes considered as potential therapeutic target genes of tangeretin (PTs) (Fig. 1B, Supplementary Table 3).

**GO and KEGG pathway enrichment analyses**

GO and KEGG pathway enrichment analyses were performed using WebGestalt (WEB-based Gene SeT AnaLysis Toolkit) with \( p < 0.05 \) as the cutoff value (70).

**PPI network and selection of hub genes**

The PPI network was analyzed using STRING-DB v11.0 (71) with confidence scores of >0.7 and visualized by Cytoscape software (72). Hub genes were selected on the basis of the highest degree score as calculated by CytoHubba plugin (73).

**Genetic alteration analysis of PTs**

Genetic alterations of the PTs were analyzed using cBioPortal (74, 75). Further connectivity analysis was performed to PTs by using the selected breast cancer study, with a cutoff value of \( p < 0.05 \).

**Kaplan–Meier survival analysis**

The prognostic values of the PTs were evaluated with the Kaplan–Meier plot (http://kmplot.com) by using the breast cancer database. The cutoff value was \( p < 0.05 \) (76), and the amount of samples was displayed in each curve.

**Validation of PTs in breast cancer and metastatic breast cancer samples**

The expression of PTs across breast cancer samples was confirmed using GEPIA (http://gepia.cancer-pku.cn), with a cutoff value of \( p < 0.05 \) (77). The reliability of the PTs in metastatic breast cancer cells was validated using ONCOMINE (https://www.oncomine.org) (78).

**Molecular docking**

Molecular docking was performed to foresee the binding sites of tangeretin with PIK3Ca (PDB ID: 4OVV), MMP9 (PDB ID: 2OW1), PTGS2 (PDB ID: 5F1A), COX-2 (PDB ID: 6COX), and IKK (PDB ID: 4KIK). All computational analyses were conducted using Windows 10, with Intel Core i5-7th Gen processor and 4 GB RAM. The docking simulation, RMSD calculation, and visualization interaction were conducted using MOE 2010 (Licensed from Faculty of Pharmacy UGM). The structure of tangeretin was downloaded from Pubchem (https://pubchem.ncbi.nlm.nih.gov) and sought for conformation and minimization by MOE using the energy minimization module. Docking simulations were performed on the binding side of the native ligand based on flexible ligand structures and rigid receptors. The London dG and Triangle matcher were selected for the score function and placement settings, respectively, in the docking simulation. The Forcefield method was used to refine the docking results of 30 settings. Docking simulation was performed using the default settings. The analysis results will conclude which conformations generate the lowest energy when tangeretin binds to the target protein.

**Abbreviations**

- COX2: Cyclooxygenase 2
- EMT: Epithelial-to-mesenchymal transition
- GO: Gene ontology
- KEGG: Kyoto Encyclopedia of Genes and Genomes
- MMP9: Matrix metalloproteinase 9
- NFkB1: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

PPI: Protein–protein interaction

PT: Potential therapeutic target genes of tangeretin

PTGS2: Prostaglandin-endoperoxide synthase 2

**Declarations**

- **Ethical Approval and Consent to participate**
  
  This article does not contain any studies with human participants or animals performed by any of the authors.

- **Consent for publication**
  
  Not applicable.

- **Availability of supporting data**
  
  All data produced by the study are disclosed in the manuscript and the additional files.

- **Competing interests**
  
  The authors declare that they have no conflict of interest.

- **Funding**
  
  This work was supported by the Penelitian Dasar Unggulan Perguruan Tinggi 2020 from the Ministry of Research and Technology, National Agency for Research and Innovation, Republic of Indonesia, Contract No. 1669/UN1/DITLIT/DIT-LIT/PT/2020.

- **Authors' contributions**
  
  AH: conception and design of the study, acquisition, analysis and interpretation of data, drafting, and revising the article, HP, NH, and MI: acquisition and analysis of data. All authors had final approval of the submitted manuscript.

- **Acknowledgements**
  
  The authors thank Badan Penerbit dan Publikasi Universitas Gadjah Mada for their assistance in writing.

- **Authors' information**
  
  Laboratory of Macromolecular Engineering, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, 55281 Yogyakarta, Indonesia

  Adam Hermawan, Muthi Ikawati

  Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, 55281 Yogyakarta, Indonesia

  Herwandhani Putri, Naufa Hanif

**References**

1. Sharma R. Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990–2016: evidence from Global Burden of Disease Study 2016. Breast cancer (Tokyo, Japan). 2019;26(4):428–45.
2. Nathanson SD, Krag D, Kuerer HM, Newman LA, Brown M, Kerjaschki D, et al. Breast cancer metastasis through the lympho-vascular system. Clin Exp Metastasis. 2018;35(5–6):443–54.

3. Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D. Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis. Mol Cancer. 2017;16(1):176-.

4. Tungsukrathi S, Petpiron N, Chanvorachote P. Molecular Mechanisms of Breast Cancer Metastasis and Potential Anti-metastatic Compounds. Anticancer research. 2018;38(5):2607–18.

5. Brack ME, Boterberg T, Depypere HT, Stove C, Leclercq G, Mareel MM. The citrus methoxyflavone tangeretin affects human cell-cell interactions. Adv Exp Med Biol. 2002;505:135–9.

6. Cheng YP, Li S, Chuang WL, Li CH, Chen GJ, Chang CC, et al. Blockade of STAT3 Signaling Contributes to Anticancer Effect of 5-Acetoxy-6,7,8,4’-Tetra-Methoxyflavone, a Tangeretin Derivative, on Human Glioblastoma Multiforme Cells. Int J Mol Sci. 2019;20(13).

7. Morley KL, Ferguson PJ, Koropatnick J. Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer letters. 2007;251(1):168–78.

8. Surichan S, Arroo RR, Tsatsakis AM, Androutsopoulos VP. Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1-mediated metabolism to the product 4’ hydroxy tangeretin. Toxicology in vitro: an international journal published in association with BIBRA. 2018;50:274–84.

9. Bracke ME, Vyncke BM, Van Larebeke NA, Bruyneel EA, De Bruyne GK, De Pestel GH, et al. The flavonoid tangeretin inhibits invasion of M04 mouse cells into embryonic chick heart in vitro. Clin Exp Metastasis. 1989;7(3):283–300.

10. Martinez Conesa C, Vicente Ortega V, Yanez Gascon MJ, Alcaraz Banos M, Canteras Jordana M, Benavente-Garcia O, et al. Treatment of metastatic melanoma B16F10 by the flavonoids tangeretin, rutin, and diosmin. J Agric Food Chem. 2005;53(17):6791–7.

11. Arivazhagan L, Sorimuthu Pillai S. Tangeretin, a citrus pentamethoxyflavone, exerts cytostatic effect via p53/p21 up-regulation and suppresses metastasis in 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. J Nutr Biochem. 2014;25(11):1140–53.

12. Zhang X, Zheng L, Sun Y, Wang T, Wang B. Tangeretin enhances radiosensitivity and inhibits the radiation-induced epithelial-mesenchymal transition of gastric cancer cells. Oncol Rep. 2015;34(1):302–10.

13. Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, et al. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med. 2016;13(12):e1002201.

14. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nature medicine. 2008;14(5):518–27.

15. Huzsno J, Grzybowska E. TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer. Oncol Lett. 2018;16(1):34–40.

16. Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Watthoo C, Busco L, et al. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO precision oncology.2018.2018.

17. Li JP, Zhang XM, Zhang Z, Zheng LH, Jindal S, Liu YJ. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine. 2019;98(18):e15449.

18. Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer discovery. 2014;4(4):405–14.

19. Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, Slagter M, de Rink I, et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572(7770):538–42.

20. Liu Z, Jiang Z, Gao Y, Wang L, Chen C, Wang X. TP53 Mutations Promote Immunogenic Activity in Breast Cancer. Journal of oncology. 2019;2019:5952836.

21. Dong Y, Cao A, Shi J, Yin P, Wang L, Ji G, et al. Tangeretin, a citrus polymethoxyflavonoid, induces apoptosis of human gastric cancer AGS cells through extrinsic and intrinsic signaling pathways. Oncol Rep. 2014;31(4):1788–94.

22. Huang H. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel, Switzerland). 2018;18(10).

23. Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 2014;5(9):2736–49.

24. Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer. 2014;14:609.

25. Shay G, Lynch CC, Fingleton B. Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix biology: journal of the International Society for Matrix Biology. 2015;44–46:200–6.

26. Guo QX, Cao YL, Hao F, Yan ZR, Wang ML, Liu XW. Tangeretin alters neuronal apoptosis and ameliorates the severity of seizures in experimental epilepsy-induced rats by modulating apoptotic protein expressions, regulating matrix metalloproteinases, and activating the PI3K/Akt cell survival pathway. Advances in medical sciences. 2017;62(2):246–53.
27. Khorshidi F, Haghighi MM, Nazemalhosseini Mojarad E, Azimzadeh P, Damavand B, Vahedi M, et al. The prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) rs5277 polymorphism does not influence risk of colorectal cancer in an Iranian population. Asian Pacific journal of cancer prevention: APJCP. 2014;15(8):3507–11.

28. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer. 2006;6:181.

29. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone. Oncogene. 2007;26(26):3789–96.

30. Chen KH, Weng MS, Lin JK. Tangeretin suppresses IL-1beta-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells. Biochem Pharmacol. 2007;73(2):215–27.

31. Yoon JH, Lim TG, Lee KM, Jeon AJ, Kim SY, Lee KW. Tangeretin reduces ultraviolet B (UVB)-induced cyclooxygenase-2 expression in mouse epidermal cells by blocking mitogen-activated protein kinase (MAPK) activation and reactive oxygen species (ROS) generation. J Agric Food Chem. 2011;59(1):222–8.

32. Sangavi P, Langeswaran K. Anti-tumorigenic efficacy of Tangeretin in Liver Cancer - An in-silico approach. Current computer-aided drug design. 2020.

33. Cartwright T, Perkins ND. C LW. NFkB1: a suppressor of inflammation, ageing and cancer. FEBS J. 2016;283(10):1812–22.

34. Concetti J, Wilson CL. NFkB1 and Cancer: Friend or Foe? Cells. 2018;7(9).

35. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, et al. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer. 2008;8:41.

36. Wang W, Nag SA, Zhang R. Targeting the NFKB signaling pathways for breast cancer prevention and therapy. Curr Med Chem. 2015;22(2):264–89.

37. Kim GC, Kwon HK, Lee CG, Verma R, Rudra D, Kim T, et al. Upregulation of Ets1 expression by NFATc2 and NFKB1/RELA promotes breast cancer cell invasiveness. Oncogenesis. 2018;7(11):91.

38. Shu Z, Yang B, Zhao H, Xu B, Jiao W, Wang Q, et al. Tangeretin exerts anti-neuroinflammatory effects via NF-kappaB modulation in lipopolysaccharide-stimulated microglial cells. Int Immunopharmacol. 2014;19(2):275–82.

39. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–44.

40. Asati V, Bharti SK, Mahapatra DK, Asati V, Budhwani AK. Triggering PI3KCA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies. Curr Pharm Design. 2016;22(39):6039–54.

41. Li B, Xu WW, Lam AKY, Wang Y, Hu H-F, Guan XY, et al. Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget. 2017;8(24):38755–66.

42. Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders. Trends Mol Med. 2018;24(10):856–70.

43. Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3KAlpha inhibitors. Science. (2019);366(6466):pp. 714–23.

44. Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology. 2020;31(3):377–86.

45. Arafa el SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, et al. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer research. 2009;69(23):8910–7.

46. Seo J, Lee HS, Ryoo S, Seo JH, Min BS, Lee JH. Tangeretin, a citrus flavonoid, inhibits PGDF-BB-induced proliferation and migration of aortic smooth muscle cells by blocking AKT activation. Eur J Pharmacol. 2011;673(1–3):56–64.

47. Liu LL, Li FH, Zhang Y, Zhang XF, Yang J. Tangeretin has anti-asthmatic effects via regulating PI3K and Notch signaling and modulating Th1/Th2/Th17 cytokine balance in neonatal asthmatic mice. Brazilian journal of medical biological research = Revista brasileira de pesquisas medicas e biologicas. 2017;50(8):e5991.

48. Zhu WB, Xiao N, Liu XJ. Dietary flavonoid tangeretin induces reprogramming of epithelial to mesenchymal transition in prostate cancer cells by targeting the PI3K/Akt/mTOR signaling pathway. Oncol Lett. 2018;15(5):433–40.

49. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2001;276(52):48997–9002.

50. Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 2010;126(2):382–94.

51. LI S-s. Jun S. Role of PI3K/AKT/mTOR pathway in the expression of Cox-2 in inhibition of human hepatocellular carcinoma cells by curcumin. Medical Journal of Chinese People's Liberation Army. 2014;39(1):30–4.
52. Mercan ME, Astort F, Giordanino EF, Martinez Caleman C, Sanchez R, Caldareri L, et al. Involvement of PI3K/Akt and p38 MAPK in the induction of COX-2 expression by bacterial lipopolysaccharide in murine adrenocortical cells. Molecular cellular endocrinology. 2014;384(1-2):43–51.

53. Anselmi Júnior RA, Souza CM A, MLVd, Netto MRM, Baldin RKS, Sebastião APM, et al. The role of Phosphatidylinositol 3 kinase (PI3K) and Cyclooxygenase-2 (COX2) in carcinogenesis of colorectal polyps. Journal of Coloproctology. 2018;38(1):1–8.

54. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014;4:64.

55. Bamodu OA, Chang HL, Ong JR, Lee WH, Yeh CT, Tsai JT. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma. Cells. 2020;9(3).

56. Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer. 2009;125(12):2863–70.

57. Hutti JE, Pfefterer AD, Russell SC, Sircar M, Perou CM, Baldwin AS. Oncogenic PI3K mutations lead to NF-kappaB-dependent cytokine expression following growth factor deprivation. Cancer research. 2012;72(13):3260–9.

58. Cheng C-Y, Hsieh HL, Hsiao L-D, Yang C-M. PI3-K/Akt/JNK/NF-κB is essential for MMP-9 expression and outgrowth in human limbal epithelial cells on intact amniotic membrane. Stem Cell Research. 2012;9(1):9–23.

59. Chen JS, Wang Q, Fu KH, Huang XH, Chen XL, Cao LQ, et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatology research: the official journal of the Japan Society of Hepatology. 2009;39(2):177–86.

60. Park JH, Cho YY, Yoon SW, Park B. Suppression of MMP-9 and FAK expression by pomeolic acid via blocking of NF-kappaB/ERK/mTOR signaling pathways in growth factor-stimulated human breast cancer cells. Int J Oncol. 2016;49(3):1230–40.

61. Singh B, Reddy PG, Goberdhan A, Walsh C, Gao J, Aksoy BA, Dogrusoz U, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 2002;16(8):984–93.

62. Lee C, Kim JS, Waldman T. Activated PI3K signaling as an endogenous inducer of p53 in human cancer. Cell cycle (Georgetown Tex). 2007;6(4):394–6.

63. Abraham AG, O'Neill E. PI3K/Akt-mediated regulation of p53 in cancer. Biochemical Society transactions. 2014;42(4):798–803.

64. Naderali E, Valipour B, Khaki AA, Soleymani Rad J, Alilhemmati A, Rahmati M, et al. Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and p53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells. Advanced pharmaceutical bulletin. 2019;9(3):470–80.

65. Li Y, Wang T, Sun Y, Huang T, Li C, Fu Y, et al. p53-Mediated PI3K/AKT/mTOR Pathway Played a Role in Ptox(Dpt)-Induced EMT Inhibition in Liver Cancer Cell Lines. Oxidative medicine and cellular longevity. 2019;2019:2531493.

66. Shen J, Deng YL, Bergqvist S, Falk MD, Liu W, Timofeevski S, et al. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design. Protein Sci. 2014;23(10):1332–40.

67. Roshini A, Jagadeesan S, Arivazhagan L, Cho Y-J, Lim J-H, Doh Y-H, et al. pH-sensitive tangeretin-ZnO quantum dots exert apoptotic and anti-metastatic effects in metastatic lung cancer cell line. Materials Science Engineering: C. 2018;92:477–88.

68. Israël A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol. 2010;2(3):a000158-a.

69. Luo J-L, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy. J Clin Investig. 2005;115(10):2625–32.

70. Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res. 2017;45(W1):W130-W7.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York NY). 2004;6(1):1–6.

Figures

(A). Chemical structure of yangeretin (B). A Venn diagram between tangeretin targets and regulatory genes of breast cancer metastasis. (C). GO enrichment, as analyzed by Webgestalt.
Figure 1

(A). Chemical structure of yangeretin (B). A Venn diagram between tangeretin targets and regulatory genes of breast cancer metastasis. (C). GO enrichment, as analyzed by Webgestalt.
(A). Chemical structure of yangeretin (B). A Venn diagram between tangeretin targets and regulatory genes of breast cancer metastasis. (C). GO enrichment, as analyzed by Webgestalt.

Figure 2

(A). Protein–protein interaction network of potential target genes of tangeretin against metastatic breast cancer, analyzed by STRING. (B). Top 20 hub genes based on highest degree score, analyzed by Cytohubba.
Figure 2

(A). Protein–protein interaction network of potential target genes of tangeretin against metastatic breast cancer, analyzed by STRING. (B). Top 20 hub genes based on highest degree score, analyzed by Cytohubba.
(A). Protein–protein interaction network of potential target genes of tangeretin against metastatic breast cancer, analyzed by STRING. (B). Top 20 hub genes based on highest degree score, analyzed by Cytohubba.

Figure 3

(A). Overview of genetic changes in MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA across 16 breast cancer studies, as analyzed by cBioportal. (B). Summary of alterations in MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA across breast cancer patients using a study from Lefebvre et al., 2016.
Figure 3

(A). Overview of genetic changes in MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA across 16 breast cancer studies, as analyzed by cBioportal. (B). Summary of alterations in MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA across breast cancer patients using a study from Lefebvre et al., 2016.
Figure 4

Overall survival of patients with breast cancer related to the mRNA level of MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA, as analyzed by GEPIA.
Overall survival of patients with breast cancer related to the mRNA level of MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA, as analyzed by GEPIA.

**Figure 4**

Overall survival of patients with breast cancer related to the mRNA level of MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA, as analyzed by GEPIA.

**Figure 5**
mRNA levels of MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA in patients with breast cancer, as analyzed by GEPIA.
Figure 6

mRNA levels of MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA in patients with metastatic breast cancer, as analyzed by ONCOMINE.
mRNA levels of MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA in patients with metastatic breast cancer, as analyzed by ONCOMINE.

Figure 6

mRNA levels of MTOR, NOTCH1, TP53, MMP9, NFKB1, PIK3CA, PTGS2, and RELA in patients with metastatic breast cancer, as analyzed by ONCOMINE.
Figure 7

Visualization of ligand interaction to PIK3 Cα, MMP9, PTGS2, and IKK using MOE.
Figure 7

Visualization of ligand interaction to PIK3 Cα, MMP9, PTGS2, and IKK using MOE.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- 20.04.05SupplementaryTableTangeretinBCMetsastasis.xlsx
- 20.04.05SupplementaryTableTangeretinBCMetsastasis.xlsx
- 20.04.05SupplementaryTableTangeretinBCMetsastasis.xlsx